Subtype
Bile Duct Neoplasm
CI-CAN-00000563Explore in graph →
Non-malignant224 active trials3 approved drugs29 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000563Explore in graph →
Clinical trials
900 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03633773 | Safety and Efficacy Evaluation of MUC-1 CART in the Treatment of Intrahepatic Cholangiocarcinoma | unknown | Phase 1 / Phase 2 | 9 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT01534637 | Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Chemotherapy and Radiation Therapy for Pancreatic Cancer | completed | Phase 2 | 22 | Wake Forest University Health SciencesOTHER | 1 | Aug 15, 2018 |
| clinicaltrials |
| NCT00832637 | Gemcitabine, Oxaliplatin, Tarceva &/or Cisplatin in HCC & Biliary Tree Cancers(Gem-ox) | terminated | Phase 2 | 33 | New Mexico Cancer Research AllianceOTHER | 1 | Jun 29, 2018 | clinicaltrials |
| NCT03527875 | Process Optimization of Preoperative Biliary Drainage in Patients With Malignant Obstructive Jaundice | unknown | N/A | 564 | Shanghai Zhongshan HospitalOTHER | 0 | Jun 6, 2018 | clinicaltrials |
| NCT02609958 | ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy | completed | Phase 2 | 32 | ASLAN PharmaceuticalsOTHER | 3 | May 29, 2018 | clinicaltrials |
| NCT03525067 | Colonization of Bile Ducts and Postoperative Infectious Complications of Pancreaticoduodenectomies | completed | — | 46 | Central Hospital, Nancy, FranceOTHER | 1 | May 15, 2018 | clinicaltrials |
| NCT01912053 | Efficacy Study of Intra-hepatic Administration of Therasphere® in Association With Intravenous Chemotherapy to Treat Cholangiocarcinoma(MispheC) | completed | Phase 2 | 41 | Center Eugene MarquisOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT03521219 | A Study of Second-line Treatment With Apatinib for Advanced Intrahepatic Cholangiocarcinoma | unknown | Phase 2 | 30 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | May 11, 2018 | clinicaltrials |
| NCT01514214 | Winged Perimeter Versus Traditional Plastic Biliary Stent for Malignant Bile Duct Obstruction | completed | N/A | 58 | University of British ColumbiaOTHER | 1 | May 2, 2018 | clinicaltrials |
| NCT00101036 | Lapatinib in Treating Patients With Locally Advanced or Metastatic Biliary Tract or Liver Cancer That Cannot Be Removed By Surgery | completed | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Apr 20, 2018 | clinicaltrials |
| NCT03132649 | Impact of Three-dimensional Visualization on Operation Strategy and Complications for Hilar Cholangiocarcinoma | unknown | — | 300 | Zhujiang HospitalOTHER | 1 | Apr 19, 2018 | clinicaltrials |
| NCT03499782 | Precise Treatment System of Biliary Malignancies Based on Special Disease Database | unknown | — | 10,000 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 17, 2018 | clinicaltrials |
| NCT00789958 | S0809: Capecitabine, Gemcitabine, and RT in Patients w/Cholangiocarcinoma of the Gallbladder or Bile Duct | completed | Phase 2 | 105 | SWOG Cancer Research NetworkNETWORK | 1 | Apr 9, 2018 | clinicaltrials |
| NCT02374489 | A Phase II Trial of LDK378 in ROS1 and /or ALK Over-expressed Advanced Intrahepatic or Hilar Cholangiocarcinoma | terminated | Phase 2 | 9 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 5, 2018 | clinicaltrials |
| NCT02638909 | Study of Oral Ceritinib in Patients With ALK and ROS1 Activated Gastrointestinal Malignancies | terminated | Phase 2 | 4 | Criterium, Inc.INDUSTRY | 1 | Apr 2, 2018 | clinicaltrials |
| NCT00588263 | Anonymous Testing of Pathology Specimens for BRCA Mutations in Ashkenazi Jewish Individuals Who Have Cancer | withdrawn | — | 0 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 19, 2018 | clinicaltrials |
| NCT03081039 | A Study of Cisplatin or Carboplatin With Gemcitabine Versus Gemcitabine Alone as Adjuvant Therapy in Patients With Resected or Ablation Intra-Hepatic Cholangiocarcinoma | withdrawn | Phase 3 | 0 | University of LouisvilleOTHER | 1 | Feb 19, 2018 | clinicaltrials |
| NCT01963325 | S-1 in Combination With Abraxane in Treating Cholangiocarcinoma | completed | Phase 2 | 50 | Yuhong LiOTHER | 1 | Feb 5, 2018 | clinicaltrials |
| NCT01721174 | Endoscopic Biliary Radiofrequency Ablation of Malignant Distal Common Bile Duct Strictures | terminated | N/A | 42 | Chinese University of Hong KongOTHER | 1 | Jan 26, 2018 | clinicaltrials |
| NCT00955721 | A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer | terminated | Phase 1 / Phase 2 | 9 | University of MiamiOTHER | 1 | Jan 3, 2018 | clinicaltrials |
| NCT01043172 | A Study of Gemcitabine as an Adjuvant Treatment for Cholangiocarcinoma After Surgical Resection | completed | Phase 2 | 72 | National Cancer Center, KoreaOTHER_GOV | 1 | Jan 3, 2018 | clinicaltrials |
| NCT00903396 | Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer | terminated | Phase 2 | 7 | Alliance for Clinical Trials in OncologyOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT03345303 | Bortezomib in Intrahepatic Cholangiocellular Carcinoma | unknown | Phase 3 | 50 | Zhengang YuanOTHER | 1 | Nov 17, 2017 | clinicaltrials |
| NCT01213758 | Changes in Liver Function After Stereotactic Body Radiation Therapy Measured by PET/CT | completed | — | 14 | University of AarhusOTHER | 1 | Oct 30, 2017 | clinicaltrials |
| NCT02106871 | Study of Sildenafil as a Therapy for Fatigue in Pancreatic Cancer(PCC) | withdrawn | Phase 1 | 0 | The University of Texas Medical Branch, GalvestonOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT03320980 | RALPPS in Patients With Hilar and Intrahepatic Cholangiocarcinoma | completed | — | 30 | Moscow Clinical Scientific CenterOTHER | 0 | Oct 25, 2017 | clinicaltrials |
| NCT01320254 | PiCCA Study (Panitumumab in Combination With Cisplatin/Gemcitabine)(PiCCA) | completed | Phase 2 | 93 | Hannover Medical SchoolOTHER | 1 | Oct 12, 2017 | clinicaltrials |
| NCT02801500 | Superior Bilioenteric Anastomosis by Magnetic Compressive Technique(CTREG) | unknown | N/A | 70 | First Affiliated Hospital Xi'an Jiaotong UniversityOTHER | 1 | Sep 21, 2017 | clinicaltrials |
| NCT00033540 | S0202 Gemcitabine and Capecitabine for Unresectable Locally Advanced Metastatic Gallbladder Cancer or Cholangiocarcinoma | completed | Phase 2 | 57 | SWOG Cancer Research NetworkNETWORK | 1 | Sep 12, 2017 | clinicaltrials |
| NCT02042443 | Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery(S1310) | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Sep 12, 2017 | clinicaltrials |
| NCT03270046 | The Effects of An Addition of Water Enema to PEG for Colon Preparation | completed | N/A | 100 | Mahidol UniversityOTHER | 0 | Sep 7, 2017 | clinicaltrials |
| NCT02825524 | Destruction of Residual Endo-biliary Dysplastic Buds After Endoscopic Ampullectomy(endoHPB) | completed | N/A | 20 | Hôpital CochinOTHER | 0 | Aug 28, 2017 | clinicaltrials |
| NCT00386516 | Study to Test the Benefit and Safety of GM-CT-01 in Combination With 5-FU to Treat Bile Duct and Gall Bladder Cancer | withdrawn | Phase 2 | 0 | Galectin Therapeutics Inc.INDUSTRY | 1 | Aug 1, 2017 | clinicaltrials |
| NCT02482454 | Radiofrquency Ablation Combined With Cytokine-induced Killer Cells for the Patients With Cholangiocarcinoma | active not recruiting | Phase 2 / Phase 3 | 50 | The First People's Hospital of ChangzhouOTHER | 1 | Aug 1, 2017 | clinicaltrials |
| NCT00085410 | Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder | terminated | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00987766 | Gemcitabine Hydrochloride, Oxaliplatin, and Erlotinib Hydrochloride in Treating Patients With Advanced Biliary Tract Cancer, Pancreatic Cancer, Duodenal Cancer, or Ampullary Cancer | completed | Phase 1 | 28 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Jul 2, 2017 | clinicaltrials |
| NCT02762721 | Analysis of Oncogenes in Intrahepatic Cholangiocarcinoma or Mixed Hepatocellular-Cholangiocarcinoma in Tumor Tissue Samples | completed | — | 131 | ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)INDUSTRY | 2 | Jun 8, 2017 | clinicaltrials |
| NCT03178409 | Combined HCC-MFCCC | completed | — | 100 | University of MilanOTHER | 0 | Jun 6, 2017 | clinicaltrials |
| NCT01673802 | The Role of Gadoxetate (Eovist) Enhanced CT in Evaluating Cholangiocarcinoma | completed | Early Phase 1 | 18 | University of Alabama at BirminghamOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT02856568 | Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma | withdrawn | Phase 1 | 0 | Mayo ClinicOTHER | 1 | May 30, 2017 | clinicaltrials |
| NCT03166436 | RFA for Malignant Biliary Obstruction | unknown | N/A | 140 | Institute for Clinical and Experimental MedicineOTHER_GOV | 1 | May 30, 2017 | clinicaltrials |
| NCT00654160 | Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Gastrointestinal Cancer | completed | Phase 1 | 7 | Mayo ClinicOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT00836992 | Quality of Life in Patients Undergoing Radiation Therapy for Primary Lung Cancer, Head and Neck Cancer, or Gastrointestinal Cancer | completed | — | 144 | Mayo ClinicOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT01303159 | Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer | terminated | N/A | 29 | Weill Medical College of Cornell UniversityOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT01798147 | Selective Internal Radiotherapy (SIRT) Versus Transarterial Chemoembolisation (TACE) for the Treatment of Cholangiocellular Carcinoma (CCC). | unknown | Phase 2 | 24 | Johannes Gutenberg University MainzOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT01673269 | Prospective Study of the Risk of Bacteremia in Directed Cholangioscopic Examination of the CBD | completed | N/A | 60 | Texas Tech University Health Sciences Center, El PasoOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT01595217 | MRCP Diagnoses EHCC Better When Combined DWI | completed | N/A | 99 | China Medical University, ChinaOTHER | 1 | May 16, 2017 | clinicaltrials |
| NCT03140007 | Diagnostic Accuracy of ERCP-guided Versus Cholangioscopy-guided Tissue Acquisition in Patients With Indeterminate Biliary Strictures Suspected to be Intrinsic .(Cholangioscopy) | unknown | N/A | 60 | Asian Institute of Gastroenterology, IndiaOTHER | 0 | May 8, 2017 | clinicaltrials |
| NCT00604266 | Coregistration of 18F-FDG-PET and MRI in the Staging of Potentially Resectable Hilar Cholangiocarcinoma: a Pilot Study(PET/MRCP) | withdrawn | — | 0 | University of TorontoOTHER | 1 | May 4, 2017 | clinicaltrials |
| NCT03117855 | Capecitabine and Y-90 Radioembolization in Treating Patients With Advanced Bile Duct Cancer in the Liver That Cannot Be Removed by Surgery | withdrawn | Phase 1 | 0 | City of Hope Medical CenterOTHER | 1 | Apr 18, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Aug 22, 2018source: clinicaltrials